Sino Biopharmaceutical Ltd (HKG: 1177) announced positive results from its Phase III and Phase II clinical studies evaluating M701, a bispecific antibody (BsAb) targeting CD3 and EpCAM, in malignant ascites (MA) and non-small cell lung cancer (NSCLC)-related malignant pleural effusion (MPE) respectively. The data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Contents
Clinical Trial Results Summary
| Study | Population | Primary Endpoint | M701 Arm | Control Arm | Benefit |
|---|---|---|---|---|---|
| Phase III | Malignant Ascites (MA) | Median Puncture-free Survival (PuFS) | 87.59 days | 49.96 days | +75% improvement |
| Median Time to Next Puncture (TTNP) | 186.72 days | 55.08 days | +239% improvement | ||
| Phase II | NSCLC-MPE (Driver gene-negative) | Median PuFS | 176 days | 42.5 days | +314% improvement |
| NSCLC-MPE (Platinum-refractory) | Median PuFS | 178 days | 53.5 days | +233% improvement | |
| NSCLC-MPE (Driver gene-negative) | Objective Response Rate (ORR) | 64.9% | 18.5% | +46.4 ppt improvement |
Drug Profile & Mechanism
- Molecule: M701 – bispecific antibody (BsAb) simultaneously targeting CD3 (T-cell engagement) and EpCAM (tumor antigen)
- Therapeutic Approach: Redirects T-cells to EpCAM-expressing tumor cells in malignant effusions, inducing localized anti-tumor activity
- Administration: Intracavitary delivery directly to affected body cavities (peritoneal or pleural)
- Safety Profile: Demonstrated favorable overall safety with significant delay in quality of life deterioration compared to standard care
Clinical Significance & Market Opportunity
- Unmet Medical Need: Malignant effusions represent a significant clinical challenge in advanced cancer, with limited effective treatment options and substantial impact on patient quality of life
- Therapeutic Innovation: M701 represents a novel localized immunotherapy approach that addresses the unique microenvironment of malignant effusions while potentially minimizing systemic toxicity
- Broad Applicability: Positive results across both malignant ascites and NSCLC-related MPE suggest potential applicability across multiple tumor types that commonly develop malignant effusions
- Regulatory Pathway: Robust Phase III data in MA provides strong foundation for regulatory submissions, while Phase II MPE data supports further development in this indication
- Commercial Potential: If approved, M701 would address a niche but high-value oncology segment with limited competition and significant unmet need
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations for M701. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech
